Pharmaceutical News

RSS

American PhRMA companies commit $25M in medicines, medical supplies and cash for Haiti relief efforts

As the need for health care assistance mounts after the recent catastrophic earthquake in Haiti, America's pharmaceutical research and biotechnology companies continue to provide help. So far, more than $25 million in medicines, medical supplies and cash have been committed to relief efforts – and that amount is still growing. The total does not include the contributions of PhRMA member company employees and the many companies committed to matching the pledges of their workers.

30 Jan 2010

PROLOR Biotech reports the EC approval of Merck's ELONVA

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today noted the European Commission (EC) approval of Merck & Co., Inc.'s ELONVA®, a long-acting CTP-modified version of the fertility drug follicle stimulating hormone (FSH).

30 Jan 2010

Canada to donate 5m doses of H1N1 vaccine to WHO; agency has received commitment of 200m vaccines

The Canadian government on Thursday announced the country would donate five million doses of H1N1 vaccines to the WHO from the country's current surplus, the Canadian Press reports (Branswell, 1/28).

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Government cracks down on drug marketing

Recent crackdown on pharmaceutical companies suggests that drug marketing remains an issue with federal authorities. The Wall Street Journal reports: "Novartis AG's agreement to settle criminal allegations involving marketing of an epilepsy drug is the latest in a string of cases showing that improper marketing practices are still a problem years after the U.S. government started cracking down on them.

30 Jan 2010

Mylan's subsidiary receives FDA approval for GoLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral Solution, USP, the generic version of Braintree Laboratories' GoLytely® laxative.

30 Jan 2010

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

laxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal®XR™ (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures.

29 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Bill and Melinda Gates announced today that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world's poorest countries.

29 Jan 2010

BioCentric Energy to grow algae strain with high EPA/DHA oil content in V3 Algae-Pro systems

BioCentric Energy is pleased to announce that the final engineering on the V3 Algae-Pro Photobioreactor system is now complete. We have received via shipment from China the 32 Corners for the V3 Alga-Pro system. Also received at the Santa Ana headquarters are the 8,000 lineal feet of proprietary, seven layer tubing. Installation of the V3 Algae-Pro system will commence over the next two weeks.

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

Econiche vaccine cited in February, 2010 issue of Scientific American

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that Econiche(TM), the world's first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157, has been cited in the February, 2010 issue of Scientific American (Vol. 302, # 2).

29 Jan 2010

Experimental vaccine protects mice and monkeys against chikungunya virus

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.

29 Jan 2010

Researchers discover new target for drugs to prevent common iron deficiency

The discovery of a major player in the body's regulation of iron levels should provide a new target for drugs that prevent common iron deficiency as well as rare, potentially deadly iron overload, researchers said.

29 Jan 2010

Mandatory influenza vaccination policy improves immunization rates among health care workers

A mandatory influenza vaccination policy improves immunization rates among health care workers, according to a recent study of a large health care organization.

29 Jan 2010

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.

29 Jan 2010

Ecstasy-related death rates in young users is a major public health issue

A paper by a University of Hertfordshire academic due to be published tomorrow (29 January 2010), reports that excess ecstasy-related death rates in young users is a cause for concern.

29 Jan 2010

Arthritis pain relief drug ALEVE now available OTC in British Columbia

This winter, British Columbians may be inspired to increase their activity level and take part in some favourite winter pastimes. For those who have joint and arthritis pain, getting back to doing the activities they love may be more of a challenge. ALEVE(R) is the first over-the-counter naproxen sodium tablet, and is now available province-wide. With just one pill, ALEVE(R) offers convenient access to pain relief for up to 12 hours.

29 Jan 2010

AccuDial Pharmaceutical introduces eight new OTC medications in Canada

AccuDial® Pharmaceutical, Inc. delivered a power-packed launch with their new family of eight over-the-counter (OTC) medications in Canada. Colorful floor displays enjoyed prominent placement in every Quebec Walmart pharmacy, and were filled with AccuDial's pain and fever, allergy, and cough and cold pediatric medications.

29 Jan 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010